PDCD1 and cancer: As immunotherapies for cancer therapy and combination treatment are attempting to improve outcomes, TTI-621 (Trillium) has been evaluated in diffuse large B-cell lymphoma in combination with the anti-PD-1 antibody pembrolizumab (NCT05507541).